



Lundbeck divests several products in the US as part of long-term business strategy

The divestiture of a portfolio of products, including Nembutal[®] supports Lundbeck's long-term strategy to focus on newer, strategic products in its US subsidiary portfolio.

H. Lundbeck A/S (Lundbeck) today announced that the company has entered into an agreement with Akorn Inc. (Akorn) whereby Akorn has acquired a portfolio of products comprising Nembutal[®] (pentobarbital sodium injection, USP), Cogentin[®] (benztropine mesylate injection) and Intravenous Sodium Diuril[®] (chlorothiazide sodium). This transaction is part of Lundbeck's long-term strategy to focus on newer, strategic products in its portfolio. As part of the agreement, Akorn will continue with Lundbeck's restricted distribution programme for Nembutal[®], which was implemented to restrict the use of the product in the US.

For more information, see [corporate press release](#).